Silmitasertib Granted Orphan Drug Status for Medulloblastoma
Silmitasertib is a first-in-class potent and highly selective inhibitor of casein kinase 2 (CK2).
Head and Neck Cancer
Tislelizumab Plus Chemotherapy as First-Line Tx Improves PFS for Nasopharyngeal Cancer
The phase 3 RATIONALE 309 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in 263 adults with recurrent or metastatic nasopharyngeal cancer (RM-NPC).
Toripalimab Gets Priority Review for Nasopharyngeal Carcinoma
The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies.
Multimodel Anesthesia May Cut Opioid Usage After Head and Neck Cancer Surgery
Study authors analyzed the safety and efficacy of using MMA for patients undergoing head and neck surgery.
HPV Vaccine Will Have Modest Impact on Oropharynx Cancer Incidence by 2045
However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults
Carboplatin Intensification Beneficial for Group 3 Medulloblastoma
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only
AAO/HNS Issue Guideline for Opioid Use After Otolaryngologic Surgery
Recommendations aim to improve postoperative pain control while reducing the risk for opioid use disorder.
New Dosing Regimen Approved for Erbitux in Colorectal, Head and Neck Cancer
The new dosing schedule is in addition to the approved weekly dosage regimen.
Tipifarnib Gets Breakthrough Tx Designation for Head and Neck Cancer
The FDA previously granted Fast Track designation to tipifarnib for this indication.
Physician Overlooks MRI, Then Claims Chiropractor Patient Should Have Read It
This month we look at a case where a jury was asked to hold a patient partially responsible for his own injury based on the fact that he had some medical background.
